Alzheimer’s disease (AD) is a devastating neurological condition affecting millions of people worldwide, with the number of cases expected to rise dramatically in the coming decades. The disease progressively destroys memory, thinking skills, and the ability to carry out daily tasks, placing a tremendous burden on both patients and caregivers. Despite recent advances, challenges remain in early diagnosis and therapeutic development. Blood-based biomarker testing presents a promising solution to improve access to critical early risk assessment along with a pathway towards accelerated clinical trials for AD.

Download the AD-Detect brochure to learn how early detection through blood-based biomarker testing is shaping the future of Alzheimer’s diagnosis and care.